Blue Cross NC policies, page 12

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

1,022 public policies Substrate tracks for Blue Cross NC, by title.

Blue Cross NC policies
PolicyDetailsCodesSource
Modifier 66G-06039 · Effective Jan 1, 2021 · Medicaid—Original policy ↗
Modifier 76: Repeat Procedure by the Same PhysicianNCBCBS-CR-RP-059499-24 · Effective Jan 1, 2021 · Medicaid—Original policy ↗
Modifier 77G-06019 · Effective Jan 21, 2021 · Medicaid—Original policy ↗
Modifier 78 (PDF)G-13001 · Medicaid—Original policy ↗
Modifier 91G-06020 · Effective Jul 17, 2024 · Medicaid—Original policy ↗
Modifier GuidelinesCommercial33Original policy ↗
Modifier GuidelinesCommercial33Original policy ↗
Modifier Guidelines8Original policy ↗
Modifier GuidelinesCommercial8Original policy ↗
Modifier Guidelines NotificationCommercial33Original policy ↗
Modifier UsageG-06006 · Effective Jan 16, 2024 · Medicaid—Original policy ↗
Modifiers 25 and 57: Evaluation and Management with Global ProceduresG-06003 · Effective May 22, 2024 · Medicaid—Original policy ↗
Modifiers 26 and TCG-15004 · Effective Oct 30, 2023 · Medicaid—Original policy ↗
Modifiers 50 and 51: Multiple and Bilateral SurgeryG-06010 · Effective Jan 1, 2021 · Medicaid—Original policy ↗
Modifiers 59, XE, XP, XS, XU: Distinct Procedural ServicesG-15001 · Effective Apr 12, 2022 · Medicaid—Original policy ↗
Modifiers 80, 81, 82, and AS: Assistant at SurgeryG-06005 · Effective Dec 19, 2023 · Medicaid—Original policy ↗
Modifiers LT and RT (PDF)G-07022 · Medicaid—Original policy ↗
Molecular Analysis for Gliomas AHS - M2139M2139 · Commercial10Original policy ↗
Molecular Analysis for Gliomas AHS - M2139M2139 · Commercial13Original policy ↗
Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020M2020 · Commercial22Original policy ↗
Molecular Markers in Fine Needle Aspirates of the ThyroidM2108 · Commercial15Original policy ↗
Molecular Markers in Fine Needle Aspirates of the Thyroid AHS - M2108M2108 · Commercial6Original policy ↗
Molecular Panel Testing of Cancers to Identify Targeted Therapy AHS - M2109M2109 · Commercial8Original policy ↗
Molecular Profiling for Cancers of Unknown Primary Origin AHS- M2065AHS-M2065 · Commercial4Original policy ↗
Molecular Testing for Cutaneous Melanoma AHS - M2029M2029 · Commercial60Original policy ↗
Molecular Testing for Pulmonary Disease AHS - M2160M2160 · Commercial5Original policy ↗
Monoclonal Antibody Imaging for Prostate CancerCommercial6Original policy ↗
MRI-Guided Focused Ultrasound (MRgFUS)Commercial11Original policy ↗
MRI-guided Laser Interstitial Thermal Therapy for Neurological IndicationsCommercial3Original policy ↗
MRI-guided Laser-induced Thermotherapy for Neurological IndicationsCommercial1Original policy ↗
Multigene Expression Assay for Predicting Colon Cancer Recurrence AHS-M2111AHS-M2111 · Commercial6Original policy ↗
Multiple and Bilateral SurgeryCommercial2Original policy ↗
Multiple and Bilateral SurgeryCommercial2Original policy ↗
Multiple and Bilateral Surgery NotificationCommercial2Original policy ↗
Multiple Delivery ServicesG-06044 · Effective Jul 17, 2024 · Medicaid—Original policy ↗
Multiple Endoscopy ServicesCommercial11Original policy ↗
Multiple Endoscopy ServicesCommercial11Original policy ↗
Multiple Procedure Payment ReductionNCBCBS-CR-RP-059503-24 · Effective Jan 1, 2021 · Medicaid—Original policy ↗
Multiple Procedure Payment Reduction Guidelines—Original policy ↗
Multiple Procedure Payment Reduction on the Technical Component (TC) of Diagnostic Cardiovascular and Ophthalmology ProceduresCommercial21Original policy ↗
Multiple Radiology Payment ReductionG-12002 · Effective Aug 15, 2022 · Medicaid—Original policy ↗
Multiple Therapy ServicesCommercial—Original policy ↗
Multiple Therapy ServicesEffective Jul 10, 2024 · Commercial—Original policy ↗
Multiple Therapy Services NotificationEffective Oct 1, 2026 · Commercial—Original policy ↗
Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101M2101 · Commercial35Original policy ↗
Mutation Testing for Limb-Girdle Muscular Dystrophies AHS – M2128M2128 · Commercial5Original policy ↗
Myocardial Sympathetic Innervation ImagingCommercial5Original policy ↗
Myoelectric Prosthetic Components for the Upper LimbCommercial25Original policy ↗
National Drug Codes (NDC) Are Required for Outpatient ClaimsNCBCBS-CR-083735-25-CPN83628 · Medicaid—Original policy ↗
National Drug Codes (NDCs) Are Required for Professional and Outpatient ClaimsNCBCBS-CR-086044-25-CPN85779 · Medicaid—Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.